

January 31, 1969

Dr. Max Schneck
Department of Clinical Pharmacology
Geigy Pharmaceuticals
Ardsley, New York 10502

Dear Dr. Schneck:

It was a pleasure chatting with you about EPA 2443.
I would be pleased to hear from you when some evidence of
its antinarcotic activity in animals has been accumulated.

Enclosed is a summary of the EEG classification data
as well as two reports describing the specific application
to cyclazocine.

Thank you for bringing this problem to my attention.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp